ABVC's Oncology Licensing to OncoX Highlights Scalable Royalty Strategy

SILICON VALLEY, CA - June 6, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that its affiliate, OncoX BioPharma Inc., has entered into a definitive agreement to acquire full ownership of the Lycopenoid Lycogen® platform, including patented manufacturing technology and commercialization rights, from Asia-Pacific Biotech Developing Inc. (APBDI). The transaction, structured as an equity-based acquisition, reflects a total value of approximately USD $4.06 million.[1]

Strategic Royalty Structure to Benefit ABVC

The Lycogen® acquisition is expected to unlock significant commercial potential for OncoX across dermatology, oncology, and nutraceutical sectors. Based on internal forecasts, OncoX estimates that, depending on future market conditions and product development milestones, cumulative revenue over the next five years could approach USD $25–30 million. Under ABVC’s existing licensing framework with OncoX, a share of these revenues will flow back to ABVC in the form of royalty payments, allowing ABVC to capitalize on downstream value. This structure exemplifies ABVC’s strategy of leveraging affiliate-driven development to achieve non-dilutive revenue growth.

Lycogen® is a next-generation lycopene-analog produced by microbial fermentation using the patented WL-APD911 strain. With potent antioxidant and anti-inflammatory properties, it has demonstrated preclinical promise in cancer-related and metabolic disease models. The acquisition positions OncoX to further develop the asset for targeted oncology indications and expand its pipeline of natural compound-based therapies. 

“OncoX’s acquisition of the Lycogen® platform further enhances ABVC Group’s position in botanical oncology innovation,” said Dr. Uttam Patil, ABVC Chief Executive Officer. “This transaction strengthens our pipeline and demonstrates our ability to convert platform assets into monetizable growth.”

Oncology Licensing Deal Already Delivering

ABVC’s direct licensing agreement with OncoX for its broader oncology pipeline includes a deal valued up to $105 million, with equity-based consideration internally valued at $25 million already received. This milestone demonstrates the viability of ABVC’s scalable revenue model via strategic product licensing and affiliate activation. 

According to Precedence Research, the global oncology drug market exceeded USD $208 billion in 2023, with projected growth to $484 billion by 2032. In parallel, the global lycopene-based ingredients market is projected to surpass $170 million by 2029, reflecting growing demand for multifunctional natural compounds in both therapeutic and consumer applications.

This transaction not only strengthens OncoX’s commercialization capability but also reflects ABVC’s long-term growth architecture - using platform assets in an attempt to drive clinical value and generate shareholder return through tiered partnerships.

About ABVC BioPharma & Its Industry

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Contact:
Uttam Patil
Email: uttam@ambrivis.com

 [1] Internal valuation

View the original release on www.newmediawire.com